the new income head of fda was interview exactly around that- the proccess of how trials are conducted. her reply was a little disappointmenting in that she indicated a long drawn out process of change.
why have a secondary end point if it isn't going to be considered, they must look at them as a back up, else all you would have is primary in all trials only
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-174
-
- There are more pages in this discussion • 250 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |